.RESEARCH STUDY HIGHLIGHT.06 August 2024.
A big randomized measured trial with cisgender females highlights the obstacles of adherence to a day-to-day oral preexposure prevention routine and also illustrates that twice-yearly shot of lenacapavir can sustain effective HIV deterrence levels over 6 months.